Compass' psychedelic-based depression treatment scores second late-stage study win

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's shares up nearly 42%, as it aims to win approval for the ...
Seeking Alpha

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

Compass Pathways Phase 3 Results Raise Hopes For FDA Approval Of Psilocybin

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
Business Insider

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 23%. The ...
Fierce Biotech

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
Benzinga.com

Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms

This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was ...
Nasdaq

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
Seeking Alpha

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from ...